Contribute Try STAT+ Today

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It’s a learning history of up and down in strategic approach in biotechnology industry

  • Saunders did not “create” Actavis nor did he engineer the Allergan acquisition, Paul Bisaro did. He has however, presided over a enormous destruction in shareholder value. Can’t wait to see the exit package he’s going to get.

    • Good point. Watson pharma reached a plateau under Dr. Chao. When Paul took over, rapid acquisitions and relocating HQ from California to New Jersey created the Actavis we are familiar with.

    • Actavis buying Iceland’s Actavis then Warner Chilcott and Forest built Actavis into strong company (all Paul Bisaro) but with two sides generic/branded. The Allergan (Inc.) deal looked good at time but Allergan Plc never lived up to “Growth Pharma” hype. Paul Bisaro built nice company and Brent could not grow the much larger disparate brands. The $ from selling generics to TEVA never got re-invested into anything sustainable and value got destroyed. So deal probably best way to salvage a tough couple of years for Allergan’s shareholders. At some point companies become too big to keep growing.

Comments are closed.